Member Info for mact4

Just find it quite an satisfying that the most recent two cheap generic medicines, this one and fluvoxamine have come, have NOT come from the Recovery programme.

Smart of RM to concentrate on the hospitalised market.

Absolutely true for patents, Mike.

But for plenty of other stuff, a simple Search function would still be very useful.

LSE chat forum could really do with even a simple search function.

Mike109:
Yes he did! Thank you for the reminder.

*Sigh*

The discussion started with "expedite manufacturing of drugs and devices" from an earlier post and the current cash in hand may not be enough to do so.

JV and licensing will likely be the way forward - certainly best for LTH and STH!

At the end of the day, we are all just speculating unless of course you (generic) secretly work for one of the interested parties!

The landscape is fast changing but will carry on trusting RM and the BoD to continue to make the best decisions for the company.

T/O will be too soon, and I believe contrary to what RM has indicated previously.

Unless of course, that is what Polygon and Polar dictate with their increasing % of voting rights.

Context.

My speculation of listing on the Nasdaq was because this could be an alternative way of raising a lot of cash, rather than parting with 20-25% with a pharma as speculated by BigJohnnyWin.

All this is just speculation in-between news!

Perhaps or maybe the US govt might assist with some upfront costs, as they have done with another Covid therapeutic (sorry I am terrible at remembering names). There is also a case for another re-rating of SP - if SNG was listed on theNASDAQ. That could also help raise the necessary cash.
Perhaps the more informed here might tell me if this idea has merit or is dead in the water!

I’m sure these scenarios would have played a part in our Activ2 progression to P3

But it felt like AGES when we were just waiting for 175 to be breached.

Too true Mike109 but I have placed a very small number at 980. They can have those few shares off me at that price ;-)

Don't speak French but this is a translation courtesy of Google

News
COVID-19: Phase III for a beta interferon to be inhaled at home

Research is advancing on new forms of COVID-19 treatment that are easy to follow at home. The AIDS Clinical Trials Group (ACTG) thus announces the passage of the experimental drug "SNG001", an inhaled formulation of beta interferon in a phase III clinical trial, within the framework of the research program "ACTIV-2", a supported program by the National Institute of Allergy and Infectious Diseases (NIAID / NIH).

ACTG is the world's largest HIV research network, but this program has recently expanded to include outpatient treatment evaluation for COVID-19. The phase III trial is to assess the effectiveness of an inhaled formulation of interferon beta in treating early symptomatic COVID-19 at home - or in out-of-hospital patients.



ACTIV-2 is the first trial to assess candidate SNG001, developed by Synairgen, a British university spin-off as an outpatient treatment for COVID-19. SNG001, a beta interferon - or natural cytokine promoting the antiviral response - is self-administered as a nebulized dose (15.6 MIU) taken once daily for 14 days. As part of the trial, the participants were trained in the use of the nebulizer by the researchers. 2 other treatments, BRII-196 / BRII-198 (a combined treatment with a monoclonal antibody) and SAB-185 (a new treatment with a polyclonal antibody) are also undergoing a phase III trial as part of the ACTIV- research program. 2.

Developing simple at-home treatment options

“This inhaled version of beta interferon expands possible treatment options for people with COVID-19 who are not hospitalized. If validated, such a treatment would simplify care for a large number of people with COVID-19 ”.



The phase III trial for SNG001 is to assess the safety and efficacy of the candidate in reducing the risk of hospitalization and death in non-hospitalized adults with mild to moderate forms of COVID-19. The study is being led by a team from the University of North Carolina and Stanford University.

An option that comes in addition to the antiviral pill from the Merck Laboratory in the process of "fast track" approval by the European Medicines Agency.

Across markets, round/whole numbers can be support/resistance because of the psychological effect.
On the hourly chart, it can be seen that around the 200 mark, initially there was support but when this support breaks down, it in turn becomes resistance.

Hey-ho: just short term price dynamics in play.
The bigger slight longer term picture is what is important and that is up!

Looking at 3 different live price charts: IG, Investing and Google.

5p difference between quoted prices! IG's spread has increased to 11p.

Thanks, iHowells. That's who I'm with. Saw the spread at 5-10p!

ihowells: who did you spreadbet with please?

Sorry, pressed "post message" too soon.

I found that my mindset is different when spreadbetting to holding actual shares. My appetite for loss is substantially reduced.

As my ISA is maxed out for this year, I've just started experimenting with spread betting this share - going Long, of course!

This got me thinking: I think some of the buys and sells may be from PI selling to cash profit or reduce loss or to meet margin calls.

After a breakout, it is very common for price to retrace to the breakout zone.